Tempus receives FDA clearance for ECG-MR AI product

Tempus said the FDA cleared its ECG-MR AI product, which analyzes 12-lead ECGs to detect signs associated with undiagnosed moderate or severe mitral regurgitation. The company said ECG-MR is its fourth FDA-cleared ECG-AI product.